Combined drug treatment strategies for major depression

Psychiatric Annals

Volumn 28, Issue 4, 1998, Pages 197-203

  Nelson, J Craig ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 11544353614     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19980401-05     Document Type: Article

References (53)

1. Nelson JC. Combined treatment strategies in psychiatry. J Clin Psychiatry. 1993; 54(9, suppl):42-49.
2. Thase ME, Rush AJ. Treatment-resistent depression. Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ, eds. New York: Raven Press, Ltd; 1995.
3. Glassman AH, Kantor SJ, Shostak M. Depression, delusions, and drug response. Am J Psychiatry. 1975;132:716-719.
4. Chan CH, Janicak PG, Davis JM. Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry. 1987;48:197-200.
5. Nelson JC, Bowers MB. Delusional unipolar depression: Description and drug response. Arch Gen Psychiatry. 1978;35:1321-1328.
6. Nelson JC. The use of antipsychotic drugs in the treatment of depression. In: Treating Resistant Depression. Zohar J, Belmaker RH, eds. New York: PMA Publishing Corp.; 1987:131-146.
7. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacologic treatment of delusional depression. Am J Psychiatry. 1985;142-430-436.
8. Nelson JC, Price LH, Jatlow PI. Neuroleptic dose and desipramine concentrations during combined drug treatment of unipolar delusional depression. Am J Psychiatry. 1986;143:1151-1154.
9. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993;54:338-342.
10. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994;151(suppl):1-35.
11. Fawcett J. Suicide risk factors in depressive disorders and in panic disorder. J Clin Psychiatry. 1992;53(suppl 3): 9-13.
12. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther. 1995;17:786-790.
13. Fawcett J, Edwards JH, Kravits HM, Jeffriess H. Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam - desipramine combination in the treatment of adult depressed outpatients. J Clin Psychopkarmacol. 1987 ; 7 : 295-310.
14. Feighner JP, Brauzer B, Gelenberg AJ, Gomez E, Kiev A, Kurland ML, Weiss BL. A placebo-controlled multicenter trial of limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness. Psychopharmacology. 1979;61: 217-225.
15. Woods SW, Nagy LM, Koleszar AS, Krystal JH, Heninger GR, Charney DS. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol. 1992;12:32-38.
16. Jacobsen FM. Low-dose trazodone as a hypnotic in patients with MAOIs and other psychotropics: a pilot study. J Clin Psychiatry. 1990;51:298-302.
17. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151;1069-1072.
18. DeMontigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psychiat. 1981;138:252-256.
19. Nelson JC. Augmentation strategies for treatment of unipolar major depression. In: Modern Problems of Pharmacopsychiatry. Rush AJ, Karger S, eds.; Basel: 1996.
20. Ontiveros A, Fontaine R, Elie R. Refractory depression: The addition of lithium to fluoxetine or desipramine. Acta Psychiat Scand. 1991;83:188-192.
21. Katona CLE, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DRL, Lock T, Burns RA, Robertson MM. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiat. 1995;166:80-86.
22. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiat. 1993;162:634-640.
23. Nelson JC: Use of lithium augmentation in refractory depression. In: Treatment Strategies in Refractory Depression. Roose S, Glassman A, eds.; Washington DC: American Psychiatric Press, Inc.; 1990:35-49.
24. Nelson JC, Mazure C. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry. 1986;143:363-366.
25. Prange AJ, Wilson IC, Rabon AM et al. Enhancement of imipramine anti- depressant activity by thyroid hormone. Am J Psychiatry. 1969;126:457-469.
26. Goodwin FK, Prange AJ, Post RM, et al. Potentiation of antidepressant effects by L-triiodotyronine in tricyclic nonresponders. Am J Psychiatry. 1982;139:34-38.
27. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry. 1989;50:385-388.
28. 3 to potentiate tricyclic antidepressant response. J Aff Dis. 1987;13:267-272.
29. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387-393.
30. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Research. 1990;32:241-251.
31. Joffe, RT. Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry. 1992;37:48-50.
32. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry. 1989;50:447-449.
33. Nelson JC, Mazure CM, Bowers MB, Jatlow PI. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-307.
34. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry. 1992;161:562-565.
35. Preskorn SH, Beber JH, Faul JC, Hirschfeld RMA. Serious adverse effets of combinin fluoxetine and tricyclic antidepressants. Am J Psychiatry. 1990;147:532.
36. Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion. Presented at the Annual Meeting of the APA, May 27, 1995.
37. Satel SL, Nelson JC. Stimulants in the treatment of depression: A critical overview. J Clin Psychiatry. 1989; 50:241-249.
38. Ayd FJ Jr, Zohar J. Psychostimulant (amphetamine or methylphenidate) therapy for chronic and treatment-resistant depression. In: Treating Resistant Depression. Zohar J, Belmaker RH, eds.; New York: PMA Publishing; 1987:343-355.
39. Wharton RN, Perel JM, Dayton PG, Malitz S. A potential clinical use of methylphenidate with tricyclic antidepressants. Am J Psychiatry. 1971;127:55-61.
40. Drimmer EJ, Gitlin MJ, Gwirtsman HE. Desipramine and methylphenidate combination treatment for depression: Case report. Am J Psychiatry. 1983;140:241-242.
41. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oridase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991;11:127-132.
42. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry. 1996;57:72-76.
43. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52:217-220.
44. Bakish D. Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry. 1991;36:749-750.
45. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54:269-271.
46. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51:248-251.
47. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15:217-222.
48. Herman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154:37-43.
49. Jones JS, Stanley M. Sertonergic agents in the treatment of refractory depression. In: Treatment Strategies for Refractory Depression. Roose SP, Glassman AH, eds.; Washington, DC: American Psychiatric Press Inc.; 1990.
50. Lader M. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. J Clin Psychiatry. 1983;44:20-24.
51. Devlin MJ, Walsh BT. Use of monoamine oxidase inhibitors in refractory depression. In: American Psychiatric Press Review of Psychiatry. Tasman A, Goldfinger SM, Kaufman CA, eds.; Washington, DC: American Psychiatric Press; 1990:9:74-90.
52. Young JPR, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J. 1979;2:1315-1317.
53. Pare CMB, Mousawi MA, Sandler M, Glover V. Attempts to attenuate the 'cheese effect': Combined drug therapy in depressive illness. J Affect Dis. 1985;9:137-141.